Clin Oncol | Volume 2, Issue 1 | Review Article | Open Access
TW Chan1*, JR Hurley2 and TJ Fahey1
1Department of Surgery, Section of Endocrine Surgery, Weill Cornell Medical College, USA
2Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medical College, USA
Radioactive iodine has been used in differentiated thyroid cancer for postoperative thyroid remnant ablation for several decades, yet its indications remain controversial. Because the potential administration of postoperative RAI plays an important role in surgical decision-making, understanding the current indications for postoperative RAI is critical in the global management of differentiated thyroid cancer. This review examines the changing indications for postoperative radioiodine from its introduction to the current guidelines.
Chan TW, Hurley JR, Fahey TJ. Postoperative Radioactive Iodine for Differentiated Thyroid Cancer: A Historical Perspective. Clin Oncol. 2017; 2: 1230.